stockrowVeracyte, Inc.
VCYT Healthcare Diagnostics & Research
Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.
- Revenue
- +15.1%
- EPS
- +62.5%
- Free cash flow
- −9.63%
Quarter to September 2026, against a year earlier
Follow VCYT
Alert me
Veracyte, Inc. (VCYT) Return on invested capital
Veracyte, Inc.'s return on invested capital over the twelve months to 30 September 2026 was 4.33%, up 0.3 percentage points from fiscal 2025 (4.03%). Over the past ten years it has ranged from −122.8% (fiscal 2015) to 4.03% (fiscal 2025) — the current reading is the highest in ten years. That is above the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 4.03% | 2.89 |
| FY2024 | 1.14% | 7.62 |
| FY2023 | −6.48% | (3.62) |
| FY2022 | −2.86% | 2.70 |
| FY2021 | −5.56% | 24.06 |
| FY2020 | −29.6% | (18.07) |
| FY2019 | −11.6% | 39.84 |
| FY2018 | −51.4% | 6.64 |
| FY2017 | −58.0% | 11.86 |
| FY2016 | −69.9% | 52.86 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| CDNA CareDx, Inc. compare | 33.6% |
| SHC Sotera Health Company compare | 9.80% |
| VCYT Veracyte, Inc. | 4.33% |
| RDNT RadNet, Inc. compare | 2.24% |
| ADPT Adaptive Biotechnologies Corporation compare | 0.00% |
| BLLN BillionToOne, Inc. compare | 0.00% |
| NEO NeoGenomics, Inc. compare | −2.97% |
| GRAL GRAIL, Inc. compare | −14.7% |
| WGS GeneDx Holdings Corp. compare | −27.7% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on VCYT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement